awmsg logo



topotecan hydrochloride (Hycamtin®)


Reference No. 317

Publication date:
20/03/2008


Appraisal information

topotecan hydrochloride (Hycamtin®) powder for concentrate for solution for infusion


Company: GlaxoSmithKline
BNF category: Malignant disease and immunosupression
NMG meeting date: 16/01/2008
AWMSG meeting date: 14/02/2008
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 0108
Ministerial ratification: 06/03/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA184) NICE GUIDANCE ISSUED NOVEMBER 2009 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Intravenous topotecan (Hycamtin®) is recommended for use within NHS Wales for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. Topotecan (Hycamtin®) should only be initiated by specialists experienced in the treatment of SCLC. Topotecan (Hycamtin®) is not presently recommended for shared care.
Final Appraisal Recommendation (FAR)
Download